Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SNX-631

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Senex Biotech

Drug class:

CDK19 inhibitor, CDK8 inhibitor

Related drugs:

‹

›

ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + SNX-631 Sensitive: D – Preclinical palbociclib + SNX-631 Sensitive : D	palbociclib + SNX-631 Sensitive: D – Preclinical palbociclib + SNX-631 Sensitive : D
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D	everolimus + SNX-631 Sensitive: D – Preclinical everolimus + SNX-631 Sensitive : D